Expression of TRAIL and death receptor DR4 in Palmer type 2 TFCC lesions
✍ Scribed by Frank Unglaub; Susanne B. Thomas; Markus W. Kroeber; Adrian Dragu; Jörg Fellenberg; Thomas Mittlmeier; Maya B. Wolf; Raymund E. Horch
- Publisher
- Springer
- Year
- 2009
- Tongue
- English
- Weight
- 347 KB
- Volume
- 130
- Category
- Article
- ISSN
- 1434-3916
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Despite improvements in chemotherapy and surgery in the treatment of osteosarcoma (OS), satisfactory results are still difficult to achieve. Novel therapeutic modalities need to be developed for osteosarcoma treatment. The combined effects of tumor necrosis factor‐related apoptosis‐indu
While TRAIL is relatively non-toxic to normal cells, it can selectively induce apoptosis in many types of transformed cells. Nevertheless, some non-small cell lung cancer (NSCLC) cells are particularly resistant to the effects of TRAIL. Here, we report that in combination with naringenin exposure to
## Abstract ## BACKGROUND. Analysis of the early molecular abnormalities that play an oncogenic role in the progression of pulmonary neoplasia may lead to the identification of useful markers for early detection and prognosis. In normal squamous epithelium, transforming growth factor β (TGFβ) regu